monoclonal antibody
C7047
concept
A monoclonal antibody is a laboratory-produced molecule engineered to bind specifically to a single epitope on an antigen, enabling targeted detection or treatment of diseases.
All labels observed (24)
| Label | Occurrences |
|---|---|
| monoclonal antibody canonical | 51 |
| biologic drug | 14 |
| therapeutic antibody | 8 |
| biosimilar medicine | 4 |
| monoclonal antibody drug | 4 |
| HER2-targeted therapy | 3 |
| bispecific monoclonal antibody | 3 |
| immunotherapy | 3 |
| monoclonal antibody cocktail | 3 |
| CD38-targeting antibody | 2 |
| anti-VEGF agent | 2 |
| immune checkpoint inhibitor | 2 |
| rituximab biosimilar | 2 |
| rituximab-containing medicinal product | 2 |
| CD20-directed cytolytic antibody | 1 |
| anti‑CD20 antibody | 1 |
| anti‑angiogenic agent | 1 |
| cancer immunotherapy | 1 |
| chimeric monoclonal antibody | 1 |
| human IgG4 monoclonal antibody | 1 |
| human monoclonal antibody | 1 |
| humanized monoclonal antibody | 1 |
| immunoglobulin G1 | 1 |
| monoclonal antibody fragment | 1 |
Description generation (CDg)
The one-sentence description above was generated by prompting gpt-5.1 with the class name and this instruction.
Instruction
generate a one-sentence description for a given conceptual class. # Response Format Return only the sentence: "Description: [one-sentence description of the conceptional class]"
Input
Class: monoclonal antibody
Generated description
A monoclonal antibody is a laboratory-produced molecule engineered to bind specifically to a single epitope on an antigen, enabling targeted detection or treatment of diseases.
Instances (68)
| Instance | Via concept surface |
|---|---|
| Hemlibra | — |
|
MabThera SC for subcutaneous formulation
surface form:
MabThera SC
|
rituximab-containing medicinal product |
| Vabysmo | bispecific monoclonal antibody |
| avelumab | — |
| nivolumab | — |
| infliximab-dyyb | — |
| infliximab-qbtx | — |
| infliximab-axxq | — |
| Andexxa | biologic drug |
| daratumumab | — |
| isatuximab | — |
| TAK-079 | — |
|
GMAB
surface form:
daratumumab
|
— |
| Ofatumumab | — |
| Teprotumumab | — |
| idarucizumab | monoclonal antibody fragment |
| fam-trastuzumab deruxtecan | HER2-targeted therapy |
|
mosunetuzumab (bispecific antibody component)
surface form:
mosunetuzumab
|
bispecific monoclonal antibody |